Molecular Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
21(9), P. 4498 - 4509
Published: July 29, 2024
Recent
emphasis
on
the
design
of
drug
delivery
systems
typically
involves
effective
transport
a
pharmaceutical
substance
to
disease
site
with
desired
therapeutic
efficacy
and
minimal
cytotoxicity.
Organelle-targeted
peptides
have
become
an
integral
part
designing
important
class
prodrug/prodrug
assemblies
for
new
supramolecular
therapeutics
owing
their
favorable
biocompatibility,
synthetic
ease,
tunability
aggregation
behavior,
functionalization
site-specificity.
However,
it
is
still
limited
due
low
selectivity.
We
designed
folic
acid-functionalized
β-cyclodextrin
(FA-CD)
as
platform
specific
selective
organelle-targeted
(such
microtubule,
lysosome,
mitochondria)
peptide
chemotherapeutics
folate
receptor
(FR)
overexpressing
cancer
cell
lines.
Low
toxicity
was
found
FA-CD
inclusion
complex
in
FR-negative
normal
cells,
but
superior
inhibition
tumor
growth
no
vivo
xenograft
model.
Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
ACS Applied Materials & Interfaces,
Journal Year:
2024,
Volume and Issue:
16(31), P. 40499 - 40514
Published: July 25, 2024
Crohn's
disease
(CD)
is
a
refractory
chronic
inflammatory
bowel
(IBD)
with
unknown
etiology.
Transmural
inflammation,
involving
the
intestine
and
mesentery,
represents
characteristic
pathological
feature
of
CD
serves
as
critical
contributor
to
its
intractability.
Here,
this
study
describes
an
oral
pyroptosis
nanoinhibitor
loaded
tumor
necrosis
factor-α
(TNF-α)
deoxyribozymes
(DNAzymes)
(DNAzymes@degradable
silicon
nanoparticles@Mannose,
Dz@MDSN),
which
can
target
macrophages
at
site
inflammation
respond
reactive
oxygen
species
(ROS)
release
drugs.
Dz@MDSN
not
only
break
cycle
in
by
degrading
TNF-α
mRNA
but
also
reduce
production
ROS
mainly
from
macrophages.
Moreover,
inhibits
excessive
epithelial
cells
through
clearance,
thereby
repairing
intestinal
barrier
reducing
translocation
bacteria
mesentery.
Consequently,
these
combined
actions
synergistically
contribute
suppression
within
both
This
likely
first
successful
attempt
field
utilizing
nanomaterials
achieve
transmural
healing
for
CD,
provides
promising
treatment
strategy
patients.
Molecular Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
21(9), P. 4498 - 4509
Published: July 29, 2024
Recent
emphasis
on
the
design
of
drug
delivery
systems
typically
involves
effective
transport
a
pharmaceutical
substance
to
disease
site
with
desired
therapeutic
efficacy
and
minimal
cytotoxicity.
Organelle-targeted
peptides
have
become
an
integral
part
designing
important
class
prodrug/prodrug
assemblies
for
new
supramolecular
therapeutics
owing
their
favorable
biocompatibility,
synthetic
ease,
tunability
aggregation
behavior,
functionalization
site-specificity.
However,
it
is
still
limited
due
low
selectivity.
We
designed
folic
acid-functionalized
β-cyclodextrin
(FA-CD)
as
platform
specific
selective
organelle-targeted
(such
microtubule,
lysosome,
mitochondria)
peptide
chemotherapeutics
folate
receptor
(FR)
overexpressing
cancer
cell
lines.
Low
toxicity
was
found
FA-CD
inclusion
complex
in
FR-negative
normal
cells,
but
superior
inhibition
tumor
growth
no
vivo
xenograft
model.
